FluMist Receives Approval for Self-Administration in the US
FluMist has become the first self-administered influenza vaccine approved in the US. This needle-free nasal spray can now be self-administered by adults up to 49 years old or given by…
Read MoreFluMist Receives Approval for Self-Administration in the US
Phase III Study Confirms Xofluza Significantly Reduces Influenza Virus Transmission
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral medication, demonstrating a significant reduction in the…
Merck Gets EU CHMP Nod for KEYTRUDA in Two Gynecologic Cancers
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending…
Positive Phase 1 Results for Personalized Vaccine in Lymphoplasmacytic Lymphoma
A team of researchers from City of Hope® and The University of Texas M.D. Anderson Cancer Center has shared promising safety and efficacy results from a Phase 1 trial involving…
Family Heart Foundation Partners with Health Systems to Use AI Model for Detecting Genetic Heart Condition
The Family Heart Foundation, a prominent research and advocacy organization, has announced the successful completion of its Flag, Identify, Network, and Deliver™ “FIND Lp(a)” machine learning model. This groundbreaking tool…
Organon Acquires Dermavant, Securing Breakthrough Dermatology Treatment VTAMA (Tapinarof) Cream 1%
Organon (NYSE: OGN), a global healthcare company dedicated to improving women’s health, has announced a definitive agreement to acquire Dermavant Sciences, a subsidiary of Roivant (NASDAQ: ROIV). Dermavant specializes in…
Cybin Announces Corporate Update and Upcoming Clinical Milestones
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments…
Neuraptive Therapeutic to Present NTX-001 Phase 2 Interim Results at 2024 ASSH Meeting
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at…
Takeda Pledges $32M to Five New Global CSR Partnerships for Health Impact
Takeda (TOKYO:4502/NYSE: TAK) has announced a commitment of JPY 4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners. This investment is part of Takeda’s…
Glycomine Granted FDA Fast Track Designation for GLM101 in PMM2-CDG Treatment
Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate…
Alzprotect Reports Positive Phase 2a Open-Label Extension Results for PSP
Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The…
CD137 Antibodies Clinical Trials & Market Opportunities 2027 – Over 80 Drugs in Development
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in…